ADMA Biologics, Inc.
ADMA
$17.10
-$0.20-1.16%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 43.58% | 62.22% | 65.15% | 63.39% | 58.69% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 43.58% | 62.22% | 65.15% | 63.39% | 58.69% |
| Cost of Revenue | 26.74% | 28.49% | 23.76% | 19.19% | 16.40% |
| Gross Profit | 62.77% | 112.56% | 141.16% | 162.94% | 170.70% |
| SG&A Expenses | 43.14% | 38.37% | 25.22% | 4.92% | -5.39% |
| Depreciation & Amortization | -84.31% | -70.19% | -46.41% | -23.13% | -2.00% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 30.81% | 30.17% | 22.96% | 13.81% | 8.34% |
| Operating Income | 79.43% | 223.04% | 468.86% | 8,679.78% | 620.61% |
| Income Before Tax | 270.19% | 4,715.18% | 545.16% | 421.36% | 197.22% |
| Income Tax Expenses | -1,558.01% | -11,193.78% | -- | -- | -- |
| Earnings from Continuing Operations | 500.57% | 5,772.73% | 799.98% | 398.48% | 186.34% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 500.57% | 5,772.73% | 799.98% | 398.48% | 186.34% |
| EBIT | 79.43% | 223.04% | 468.86% | 8,679.78% | 620.61% |
| EBITDA | 71.97% | 188.29% | 348.75% | 1,225.29% | 1,189.16% |
| EPS Basic | 491.41% | 5,113.71% | 768.86% | 368.92% | 176.25% |
| Normalized Basic EPS | 109.51% | 433.52% | 24,150.00% | 507.99% | 251.52% |
| EPS Diluted | 519.51% | 4,023.15% | 727.08% | 349.91% | 168.72% |
| Normalized Diluted EPS | 108.76% | 427.00% | 27,091.67% | 492.63% | 246.85% |
| Average Basic Shares Outstanding | 4.14% | 4.25% | 4.07% | 5.63% | 8.14% |
| Average Diluted Shares Outstanding | 4.87% | 6.39% | 7.18% | 7.73% | 11.20% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |